{"url_path":"/sec/celz/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 Controls and Procedures**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1187953/0001477932-26-002893-index.html","accession_number":"0001477932-26-002893","cik":"0001187953","ticker":"CELZ","issuer_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1187953/0001477932-26-002893-index.html","primary_entity_key":"0001187953","primary_entity_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC."},"word_count":224,"has_tables":true,"body_markdown":"**Item 4. Controls and Procedures**\n\n \n\n***Evaluation of disclosure controls and procedures***\n\n \n\nOur management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.\n\n \n\n**Changes in internal control over financial reporting**\n\n \n\nThere were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\n\n \n\n \n\n24\n\n*Table of Contents*\n\n \n\n**PART II – OTHER INFORMATION**"}